Keywords: gsk, advair, diskus, approved, copd, exacerbations, fda
GSK's Advair Diskus approved for COPD exacerbations by US FDA
Article | 05 May 2008
The US Food and Drug Administration has approved UK drug major GlaxoSmithKline's Advair Diskus 250/50 (fluticasone propionate 250mcg and salmeterol 50mcg ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
